Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29825453 | 0.85 | MAOA (0.44) | MAOAMAOBCYP3A4MAPTKDM4E | |
| SCHEMBL18604654 | 0.85 | MAOA (0.44) | MAOAMAOBCYP3A4MAPTKDM4E | |
| SCHEMBL5843310 | 0.82 | CYP3A4 (0.64) | MAOANR3C2MAOBCYP3A4MAPT | |
| SCHEMBL6567347 | 0.81 | NR3C2 (0.57) | NR3C2MAPTKDM4EALDH1A1CYP1A2 | |
| SCHEMBL409370 | 0.81 | NR3C2 (0.57) | NR3C2MAPTKDM4EALDH1A1CYP1A2 | |
| SCHEMBL23776020 | 0.80 | NR3C2 (0.46) | MAOANR3C2CYP3A4MAPTALDH1A1 | |
| SCHEMBL16408144 | 0.80 | NR3C2 (0.46) | NR3C2CYP3A4MAPTKDM4EALDH1A1 | |
| SCHEMBL27991179 | 0.80 | DHFR (0.34) | MAOANR3C2MAOBCYP3A4MAPT | |
| Iodide SCHEMBL31634397 | 0.79 | NR3C2 (0.55) | NR3C2MAPTKDM4EALDH1A1CYP1A2 | |
| Bromide SCHEMBL6737911 | 0.79 | NR3C2 (0.55) | NR3C2MAPTKDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697737-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110071145-A1 | Raf Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-7846959-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20080009488-A1 | Raf Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| EP-1751124-A2 | RAF MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005112932-A2 | RAF MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009488-A1 | Raf Modulators and Methods of Use | BRAF, RAF1, ARAF | MAOA 2411/4885NR3C2 3352/4885MAOB 1623/4885 |
| US-20110071145-A1 | Raf Modulators And Methods Of Use | BRAF, RAF1, ARAF | MAOA 1151/4885NR3C2 2752/4885MAOB 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.